BIRC5 and breast carcinoma: Thereby, the fact that eugenol can inhibit both E2F1 and survivin in vitro and in tumor xenografts, indicates that eugenol could be used to consolidate the adjuvant treatment of breast cancer patients, especially the clinically aggressive ER-negative types, whose prognosis is still poor and clinically characterized as more aggressive and less responsive to standard treatments[30,31].